Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Tissue fibrosis causes organ failure and death in patients with systemic sclerosis (SSc), but clearly effective anti-fibrotic therapies are not available. The tyrosine kinase inhibitor (TKI) imatinib, which blocks the pro-fibrotic c-Abl kinase and PDGF receptor, is currently evaluated in clinical...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2010-08-01
|
Series: | Swiss Medical Weekly |
Subjects: | |
Online Access: | https://www.smw.ch/index.php/smw/article/view/1177 |